Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128503) titled 'A Multicenter, Prospective, Randomized Phase II Trial of Response-Adapted De-escalation Strategy Based on Tumor Response During Concurrent Chemoradiotherapy in HPV-Positive Oropharyngeal Squamous Cell Carcinoma' on July 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Fudan University Shanghai Cancer Center
Condition:
HPV-positive oropharyngeal squamous cell carcinoma
Intervention:
Standard CCRT:Radiotherapy: 70 Gy / 35 fractions
Concurrent chemotherapy: Cisplatin 80mg/m2, administered over 3 days, every 3 weeks, for 2 cycles.
Individualized reduced-dose therapy group (Selectivel...